The OPTION trial compared left atrial appendage closure with Watchman FLX device to oral anticoagulation after ablation for atrial fibrillation. The trial included 1,600 patients at moderate-high risk for stroke. Results showed similar thromboembolic protection but superior bleeding outcomes with LAA closure compared to oral anticoagulation. At 36 months, LAA closure had lower rates of major bleeding and non-procedure-related major bleeding. The study concluded that Watchman FLX is a safe and effective option for AF ablation patients, providing similar thromboembolic protection and better bleeding outcomes compared to oral anticoagulation.
Source link
Left atrial appendage closure safe, effective first-line option for AF ablation patients
